Interim results from ongoing Phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication

Abstract

Aim: We aimed to further investigate the role of hepcortespenlisimut-L (Hepko-V5 or V5), a new oral immunotherapy developed by us, for hepatocellular carcinoma (HCC) indication.

Methods: The interim data from ongoing Phase III placebo-controlled, randomized trial were evaluated on the initial group of patients in advanced stage of HCC with emphasis on liver function and tumor marker alpha-fetoprotein levels. Additionally, an in vitro study was undertaken to elucidate the mechanism of action of V5 by measuring with flow cytometry the expression of cytokines such as IL-2, INF-γ, and TNF-α and cell activation markers CD69 and Ki67 on CD4- and CD8-positive lymphocytes isolated from peripheral blood of healthy volunteers.

Results: As early as one month after treatment initiation, there was a clear improvement in alanine transaminase, aspartate transaminase, alkaline phosphatase, and bilirubin levels among HCC patients who received daily dose of V5, but not in the placebo group. Additionally, alpha-fetoprotein (AFP) levels among V5 recipients decreased, while in the placebo group they rose. Clinical results are in line with in vitro observations indicating immune activation, as evidenced by many-fold enhancement of CD69, Ki67, and INF-γ expression and at the same time marked anti-inflammatory effect resulting in 10-fold decrease in TNF-α output and lack of influence on IL-2 production.

Conclusion: Hepcortespenlisimut-L, a tableted oral formulation derived from heat-inactivated pooled blood of patients with HCC and viral hepatitis shows beneficial clinical effect, as demonstrated by improvement in liver function and reduction of tumor marker AFP levels. These correlate with in vitro observations showing potent activation of the immune response and pronounced oral tolerance effect.

Keywords

Hepatocellular carcinoma / alpha-fetoprotein / alanine transaminase / aspartate transaminase / IL-2 / INF-γ / TNF-α / CD69 / Ki67 / CD4 / CD8 / T lymphocytes

References

[1] Petrick JL,Znaor A,Laversanne M.International trends in hepatocellular carcinoma incidence, 1978-2012..Int J Cancer2019;Epub ahead of print doi: 10.1002/ijc.32723

[2] Rawla P,Muralidharan P.Update in global trends and aetiology of hepatocellular carcinoma..Contemp Oncol (Pozn)2018;22:141-50 PMCID:PMC6238087

[3] Ringelhan M,O’Connor T,Heikenwalder M.The immunology of hepatocellular carcinoma..Nat Immunol2018;19:222-32

[4] Pinter M.Review article: systemic treatment of hepatocellular carcinoma..Aliment Pharmacol Ther2018;48:598-609 PMCID:PMC6120553

[5] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[6] Longo V,Gnoni A,Delcuratolo S.Emerging role of immune checkpoint inhibitors in hepatocellular carcinoma..Medicina (Kaunas)2019;55:E698 PMCID:PMC6843273

[7] Tarakanovskaya MG,Batchuluun P,Purevsuren G.Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L..J Hepatocell Carcinoma2017;4:59-69 PMCID:PMC5396941

[8] Batdelger D,Jirathitikal V.Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C..Vaccine2008;26:2733-7

[9] Batdelger D,Dahgwahdorj Y,Oyunbileg J.Clinical experience with therapeutic vaccines designed for patients with hepatitis..Curr Pharm Des2009;15:1159-71

[10] Bourinbaiar AS,Butov DA,Efremenko YuV.Immune approaches in tuberculosis therapy: a brief overview..Exp Rev Anti-infect Ther2012;10:381-9

[11] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[12] Zongyi Y.Immunotherapy for hepatocellular carcinoma..Cancer Lett2019;470:8-17

[13] Baradaran Noveiry B,Khalili N,Greten TF.Specific immunotherapy in hepatocellular cancer: a systematic review..J Gastroenterol Hepatol2017;32:339-51 PMCID:PMC6377153

[14] Butterfield LH,Gamblin TC.Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients..J Transl Med2014;12:86 PMCID:PMC4021640

[15] Nobuoka D,Sawada Y,Nakatsura T.Peptide vaccines for hepatocellular carcinoma..Hum Vaccin Immunother2013;9:210-2 PMCID:PMC3667940

[16] Buonaguro L.Developments in cancer vaccines for hepatocellular carcinoma..Cancer Immunol Immunother2016;65:93-9

[17] Shen L,Lee H,Johnston SA.RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines..Sci Rep2019;9:1-3 PMCID:PMC6775166

[18] Silin DS,Jirathitikal V.Oral vaccination: where we are?.Expert Opin Drug Deliv2007;4:323-40

[19] Alspach E,Miceli AP,DuPage M.MHC-II neoantigens shape tumour immunity and response to immunotherapy..Nature2019;574:696-701 PMCID:PMC6858572

[20] Hilmi M,Calderaro J,Pawlotsky JM.Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions..J Immunother Cancer2019;7:333 PMCID:PMC6884868

[21] Rafei H,Rezvani K.Editorial: cellular therapies in cancer..Front Immunol2019;10:2788 PMCID:PMC6890829